Prof. Wilke consultation on claims data use in scientific research

Prof. Thomas Wilke, partner at INGRESS, was invited by China Health Insurance Research Association (CHIRA) in Beijing, China. CHIRA is a non-profit community Chinese organization caring about the development of the Chinese healthcare system. At the 15th of April in Beijing, Prof Wilke gave a presentation how to use claims and electronic healthcare data in scientific

Lees meer

Urinary tract infections cost in type 2 DM patients, data from 456,586 German patients

INGRESS published a paper about cost of urinary tract infections in type 2 diabetes patients; 456,586 T2DM-patients were included from a regional German healthcare fund database. We calculated UTI-associated resource costs. We observed 48,337 UTI events. The direct mean resource-based costs were €315.90 per UTI event. Healthcare costs per patient year were €3,916 higher in

Lees meer

Welcome Fränce to the team!

Fränce holds a Master of Science in Demography from the University of Rostock. She has been working for three years at the Max-Planck-Institute for demographic research. As a junior researcher, Fränce will support observational and real-world evidence studies. Welcome Fränce to the team!

Lees meer

First DCE analysis in age-related wet macular degeneration!

The Ingress-health team recently published the very first discrete-choice based preference analysis in patients with age-related wet macula degeneration. This technique had not been used so far in this disease, so this is the first worldwide publication in this respect. It is published in the high-impact ophthalmology journal “Ophthalmology”. The results of the analysis show

Lees meer

Non-persistence/non-adherence in T2DM patients; insights from UK and Germany real-world setting

In our recently published work, we have utilized data from two large retrospective datasets: a German claims dataset and the UK General Practitioner (GP)-based Clinical Practice Research Datalink (CPRD) dataset (2010–2012). The study included 1,905 and 1,627 type 2 diabetes mellitus (T2DM) patients receiving glucagon-like peptide-1 (GLP-1) receptor agonists from the UK and Germany, respectively.

Lees meer

What risk factors are associated with UTI in T2DM patients?

Insights from a real-world setting, 456,586 T2DM German patients. In our recently published work we investigated urinary tract infection (UTI) incidence among Type 2 Diabetes mellitus (T2DM) patients in Germany. Moreover, we aimed to identify risk factors associated with UTI incidence/recurrence. A total of 456,586 T2DM- patients were identified. Overall, the UTI event rate was

Lees meer

Meet us at ISPOR Milan 2015

The ISPOR 18th Annual European Congress that will be held in Milan this year, 7-11 November 2015, is almost there. We, Ingress-Health, are having a booth this year: stand No. 1010. Visit us for a little chat! In addition to several poster presentations, Ingress-Health is organizing a workshop titled “Availability, strengths and limitations of real-world

Lees meer

Meet us at 51st European Association for the Study of Diabetes (EASD) Annual Meeting

The 51st (EASD) Annual Meeting is taking place at Stockholm, Sweden, 14-18 September 2015. Prof. Thomas Wilke will be giving an oral presentation regarding our recent interesting study “Treatment characteristics and outcomes associated with sulphonylurea versus metformin therapy in incident type 2 diabetes mellitus patients: results of the German CREST study”. In this study, out

Lees meer

Welcome Ilse to Ingress-health!

Ingress-health welcomes Ilse as latest member of the team. Ilse will support health economic and outcomes research projects as junior researcher. She recently obtained a European Master’s degree in Health Economics and Management. This double degree program consists of a MSc in Health Economics, Policy and Law from the Erasmus University Rotterdam, NL and a

Lees meer